aTyr Pharma is a public biotherapeutics company (Nasdaq: LIFE) that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases. The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 (NRP2) that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease (ILD), a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients. More information...
According to PR-model, atyrpharma.com is ranked 2,412,340th in multilingual Wikipedia, in particular this website is ranked 1,322,813th in English Wikipedia.
The website is placed before anothersomething.org and after saspc.asn.au in the BestRef global ranking of the most important sources of Wikipedia.
